These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16970764)

  • 1. Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients.
    Rozenfeld PA; Croxatto O; Ebner R; Fossati CA
    Clin Exp Ophthalmol; 2006; 34(7):689-94. PubMed ID: 16970764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.
    Üçeyler N; Schröter N; Kafke W; Kramer D; Wanner C; Weidemann F; Sommer C
    PLoS One; 2016; 11(11):e0166484. PubMed ID: 27851774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
    Valbuena C; Leitão D; Carneiro F; Oliveira JP
    Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
    Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
    Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits.
    Svarstad E; Leh S; Skrunes R; Kampevold Larsen K; Eikrem Ø; Tøndel C
    Nephron; 2018; 138(1):13-21. PubMed ID: 28848191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
    Manwaring V; Boutin M; Auray-Blais C
    Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antibody binding-based fluorescent assay for the rapid quantification of globotriaosylceramide levels in human Fabry cells.
    Ng AWR; Narayanan K
    Anal Biochem; 2021 Sep; 628():114287. PubMed ID: 34119486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease.
    Üçeyler N; Böttger J; Henkel L; Langjahr M; Mayer C; Nordbeck P; Wanner C; Sommer C
    J Intern Med; 2018 Oct; 284(4):427-438. PubMed ID: 29974530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
    Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
    Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.
    Liguori R; Incensi A; de Pasqua S; Mignani R; Fileccia E; Santostefano M; Biagini E; Rapezzi C; Palmieri S; Romani I; Borsini W; Burlina A; Bombardi R; Caprini M; Avoni P; Donadio V
    PLoS One; 2017; 12(7):e0180581. PubMed ID: 28672034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
    De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
    Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
    Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
    Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
    Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
    Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
    Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.